海爾生物(688139.SH)擬2700萬元出售海美康濟75%股權
格隆匯1月5日丨海爾生物(688139.SH)公佈,公司於2020年1月3日召開第一屆董事會第十四次會議,審議通過了《關於出售控股子公司股權相關事項的議案》,同意海爾生物將其持有的青島海美康濟生物科技有限公司(以下簡稱"海美康濟")75%股權(以下簡稱"交易標的")轉讓給上海惠黔企業管理合夥企業(有限合夥)(以下簡稱"上海惠黔"),轉讓對價為人民幣2700萬元,所得款項將用於發展公司主營業務。
海美康濟主要從事分子診斷POCT相關產品的研究開發、生產和銷售業務。其中,公司持有海美康濟75%的股權。交易完成後,公司不再持有海美康濟股權,上海惠黔持有海美康濟75%股權,成為海美康濟控股股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.